357 related articles for article (PubMed ID: 12827720)
1. This Dutchman is flying.
Watson N
Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
[No Abstract] [Full Text] [Related]
2. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
Stipp D
Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
[No Abstract] [Full Text] [Related]
3. The quiet revolution.
Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
[No Abstract] [Full Text] [Related]
4. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
5. Hyseq-Variagenics merger signals end of the line.
Hodgson J
Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
[No Abstract] [Full Text] [Related]
6. Genzyme and Isis strike megadeal.
Mack GS
Nat Biotechnol; 2008 Mar; 26(3):251-3. PubMed ID: 18327216
[No Abstract] [Full Text] [Related]
7. What mergers can do for you.
Acharya A
Nat Biotechnol; 2011 Jun; 29(6):477-9. PubMed ID: 21796820
[No Abstract] [Full Text] [Related]
8. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
9. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
10. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
11. Growing against the grain.
Boyle M
Fortune; 2004 May; 149(9):148-9, 152, 154 passim. PubMed ID: 15124331
[No Abstract] [Full Text] [Related]
12. Amgen asks judge for speedy ruling in patent case.
Nephrol News Issues; 1999 Dec; 13(12):14. PubMed ID: 11984928
[No Abstract] [Full Text] [Related]
13. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
14. The Orphan Drug Act: an engine of innovation? At what cost?
Rohde DD
Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
[No Abstract] [Full Text] [Related]
15. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
16. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
17. BIO and biogenerics.
Feldbaum CB
Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
[No Abstract] [Full Text] [Related]
18. The lengthening handshake.
Osborne R
Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
[No Abstract] [Full Text] [Related]
19. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
20. Marketplace. How drug company mergers affect HMOs and hospitals.
Moskowitz DB
Faulkner Grays Med Health; 1997 Jun; 51(23):suppl 2 p.. PubMed ID: 10167794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
